{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:32:39Z","timestamp":1759332759956,"version":"3.40.5"},"reference-count":25,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"unspecified","delay-in-days":345,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2732494X23005004_as1\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>To describe antimicrobial therapy used for multidrug-resistant (MDR) <jats:italic>Acinetobacter spp.<\/jats:italic> bacteremia in Veterans and impacts on mortality.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23005004_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>This was a retrospective cohort study of hospitalized Veterans Affairs patients from 2012 to 2018 with a positive MDR <jats:italic>Acinetobacter spp.<\/jats:italic> blood culture who received antimicrobial treatment 2 days prior to through 5 days after the culture date. Only the first culture per patient was used. The association between treatment and patient characteristics was assessed using bivariate analyses. Multivariable logistic regression models examined the relationship between antibiotic regimen and in-hospital, 30-day, and 1-year mortality. Generalized linear models were used to assess cost outcomes.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23005004_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>MDR <jats:italic>Acinetobacter spp.<\/jats:italic> was identified in 184 patients. Most cultures identified were <jats:italic>Acinetobacter baumannii (90%)<\/jats:italic>, 3% were <jats:italic>Acinetobacter lwoffii,<\/jats:italic> and 7% were other <jats:italic>Acinetobacter species.<\/jats:italic> Penicillins\u2014\u03b2-lactamase inhibitor combinations (51.1%) and carbapenems (51.6%)\u2014were the most prescribed antibiotics. In unadjusted analysis, extended spectrum cephalosporins and penicillins\u2014\u03b2-lactamase inhibitor combinations\u2014were associated with a decreased odds of 30-day mortality but were insignificant after adjustment (adjusted odds ratio (aOR) = 0.47, 95% CI, 0.21\u20131.05, aOR = 0.75, 95% CI, 0.37\u20131.53). There was no association between combination therapy vs monotherapy and 30-day mortality (aOR = 1.55, 95% CI, 0.72\u20133.32).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23005004_as4\">\n\t    <jats:title>Conclusion:<\/jats:title>\n\t    <jats:p>In hospitalized Veterans with MDR <jats:italic>Acinetobacter spp<\/jats:italic>., none of the treatments were shown to be associated with in-hospital, 30-day, and 1-year mortality. Combination therapy was not associated with decreased mortality for MDR <jats:italic>Acinetobacter spp.<\/jats:italic> bacteremia.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/ash.2023.500","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T07:43:11Z","timestamp":1702366991000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment effectiveness of antibiotic therapy in Veterans with multidrug-resistant <i>Acinetobacter spp.<\/i> bacteremia"],"prefix":"10.1017","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-527X","authenticated-orcid":false,"given":"Amanda","family":"Vivo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-9238","authenticated-orcid":false,"given":"Margaret A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-7689","authenticated-orcid":false,"given":"Geneva M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-875X","authenticated-orcid":false,"given":"Martin E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-8288","authenticated-orcid":false,"given":"Charlesnika T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"S2732494X23005004_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix411"},{"key":"S2732494X23005004_ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113239"},{"key":"S2732494X23005004_ref9","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.11.1073"},{"key":"S2732494X23005004_ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1392-4"},{"key":"S2732494X23005004_ref16","unstructured":"16. Center of Excellence for Mortality Data Repository. Joint Department of Veterans Affairs (VA) and Department of Defense (DoD) Suicide Data Repository \u2013 National Death Index (NDI), 2013-2018. http:\/\/vaww.virec.research.va.gov\/Mortality\/Overview.htm."},{"key":"S2732494X23005004_ref15","unstructured":"15. Center of Excellence for Mortality Data Repository. Joint Department of Veterans Affairs (VA) and Department of Defense (DoD) Suicide Data Repository \u2013 National Death Index (NDI), 2013-2018. http:\/\/www.dspo.mil\/Portals\/113\/Documents\/SDR%20Fact%20Sheet.pdf."},{"key":"S2732494X23005004_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit253"},{"key":"S2732494X23005004_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2124-9"},{"key":"S2732494X23005004_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl130"},{"key":"S2732494X23005004_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"S2732494X23005004_ref18","unstructured":"18. Kaye, KS , University of Michigan. Trial for the treatment of extensively drug-resistant Gram-negative Bacilli. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597973."},{"key":"S2732494X23005004_ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868020-00003"},{"key":"S2732494X23005004_ref2","unstructured":"2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed 29 July 2021."},{"key":"S2732494X23005004_ref6","unstructured":"6. Sanford Guide. Acinetobacter spp. (baumannii complex, pittii, nosocomialis). https:\/\/dva.sanfordguide.com\/sanford-guide-online\/disease-clinical-condition\/acinetobacter-baumannii-pittii-nosocomialis."},{"key":"S2732494X23005004_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"S2732494X23005004_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"S2732494X23005004_ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-019-0706-5"},{"key":"S2732494X23005004_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.08.007"},{"key":"S2732494X23005004_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0371-8"},{"key":"S2732494X23005004_ref24","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666190408095811"},{"key":"S2732494X23005004_ref1","unstructured":"1. Centers for Disease Control and Prevention. Acinetobacter in healthcare settings. https:\/\/www.cdc.gov\/hai\/organisms\/acinetobacter.html. Accessed July 30, 2021."},{"key":"S2732494X23005004_ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.68538"},{"key":"S2732494X23005004_ref12","unstructured":"12. Infectious Disease Society of America. IDSA 2023 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections, 2023. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/#Carbapenem-ResistantAcinetobacterbaumannii%C2%A0."},{"key":"S2732494X23005004_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1013"},{"key":"S2732494X23005004_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/653120"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X23005004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T07:43:15Z","timestamp":1702366995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X23005004\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"alternative-id":["S2732494X23005004"],"URL":"https:\/\/doi.org\/10.1017\/ash.2023.500","relation":{},"ISSN":["2732-494X"],"issn-type":[{"type":"electronic","value":"2732-494X"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e230"}}